Furthermore, treatment of ESCC cells with recombinant CCL22 protein (rCCL22; 5, 25, and 50 ng/ml) for 24 h increased the invasive ability of ESCC cells in a dose-dependent manner (Fig. 3B). This evidence concerns the gene CCL22 and esophageal squamous cell carcinoma.